Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Generalized Myasthenia Gravis
NCT06517758Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of Iptacopan in myasthenia gravis (MG), sponsored by Novartis. Started Jul 2024; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06517758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517758.